#USA #Milford #Waters Corporation #BioResolve #Protein A

Accelerating Antibody Development with BioResolve Protein A Affinity Columns

Waters Corporation has taken a significant step forward in the realm of biotherapy development by launching the BioResolve™ Protein A Affinity Columns featuring groundbreaking MaxPeak™ Premier Technology. This innovation represents a pivotal addition to Waters' suite of products aimed at resolving challenges in large molecule separations.

Overview of the Launch

On May 28, 2025, Waters Corporation (NYSE: WAT) introduced these columns, positioning them as instrumental tools for the efficient measurement of antibody titer. The columns are crucial in the upstream bioprocessing phase, enabling companies to obtain results earlier than previously possible. They facilitate faster optimization of methods in the downstream development of biologics, paving the way for enhanced agility in discovering, optimizing, and manufacturing antibody-based therapies.

Enhanced Measurement Capabilities

The BioResolve Protein A Affinity Columns distinguish themselves by offering up to seven times greater sensitivity compared to current leading options. This remarkable achievement is attributed to the use of novel, non-porous 3.5 μm particles, which allow for accurate quantification of antibody titers even at lower concentrations. The design not only permits less sample consumption but also enables simultaneous analysis of antibody titer and aggregate levels—improving efficiency without sacrificing quality.

Dr. Udit Batra, the President and CEO of Waters Corporation, emphasized the direct impact of this innovation on pharmaceutical outcomes. The advancement targets one of the primary bottlenecks in therapeutic development: the time it takes to identify and optimize cell lines for antibody production. The incorporation of these advanced columns is expected to streamline workflows significantly, leading to quicker therapeutic solutions for patients.

Streamlining Workflows

The columns complement size exclusion chromatography (SEC) columns, allowing for a streamlined process by merging titer concentration and aggregate analysis within a single run on any liquid chromatography (LC) system. “This innovation greatly simplifies dual workflows for simultaneous titer and aggregate analysis,” remarked Arnaud Delobel, RD and Innovation Director at Quality Assistance. This integration into existing LC/MS setups facilitates real-time analytical assessments of in-process antibody samples without the need for prior purification, thus reducing project turnaround times and expediting the pathway to market for biotherapeutics.

Product Availability

Waters has made these cutting-edge columns available in two distinct formats: 2.1 x 20 mm and 3.9 x 5 mm, and they can be ordered from Waters' website. This latest offering further solidifies Waters’ commitment to enhancing tools for biomolecule characterization, ensuring scientific teams can expedite the development of safe, effective, and accessible biotherapeutics.

Conclusion

The introduction of the BioResolve Protein A Affinity Columns marks a significant milestone in the field of bioprocessing. It portrays Waters Corporation's dedication to innovation in scientific research and medicine, enabling labs around the globe to foster accelerated development timelines for lifesaving therapies. With these advancements, Waters is poised to continue leading the way in crucial medical innovations, helping to bring effective solutions to patients faster. For more detailed information about the BioResolve Protein A Affinity Columns, including application notes and specifications, visit Waters Corporation.

For further inquiries, please contact:
Molly Gluck
Head of External Communications
Waters Corporation
Email: [email protected]
Mobile: +1.617.833.8166